766 related articles for article (PubMed ID: 24548978)
21. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
22. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
23. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
24. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
25. Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation).
Nakade S; Komaba J; Ohno T; Kitagawa J; Furukawa K; Miyata Y
Int J Clin Pharmacol Ther; 2008 Jan; 46(1):42-7. PubMed ID: 18218297
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
27. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
28. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
29. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
30. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.
Lim A; Wang-Smith L; Kates J; Laurent A; Kumar P; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):450-5. PubMed ID: 23927483
[TBL] [Abstract][Full Text] [Related]
31. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
33. Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers.
Johnson FK; Mudd PN; Janmohamed SG
Clin Pharmacol Drug Dev; 2015; 4(3):193-202. PubMed ID: 27140799
[TBL] [Abstract][Full Text] [Related]
34. Metronidazole immediate release formulations: a fasting randomized open-label crossover bioequivalence study in healthy volunteers.
de Freitas Silva M; Schramm SG; Kano EK; Koono EE; Manfio JL; Porta V; dos Reis Serra CH
Arzneimittelforschung; 2012 Oct; 62(10):490-5. PubMed ID: 22918856
[TBL] [Abstract][Full Text] [Related]
35. Comparative fasting bioavailability and pharmacokinetic properties of 2 formulations of glucosamine hydrochloride in healthy Chinese adult male volunteers.
Wu H; Liu M; Wang S; Zhao H; Yao W; Feng W; Yan M; Tang Y; Wei M
Arzneimittelforschung; 2012 Aug; 62(8):367-71. PubMed ID: 22791244
[TBL] [Abstract][Full Text] [Related]
36. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
[TBL] [Abstract][Full Text] [Related]
37. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Wong S; Krejsa C; Lee D; Harris A; Simard E; Wang X; Allard M; Podoll T; O'Reilly T; Slatter JG
Clin Pharmacol Drug Dev; 2022 May; 11(5):640-653. PubMed ID: 35172043
[TBL] [Abstract][Full Text] [Related]
39. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G; Xu E; Thipphawong J; Gupta SK
BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
